Neural and nonneural cells in injured tissues produce … 2. Some companies that are related to Mylan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX) and Endo International (ENDP). Novartis and Intec have mutually agreed to proceed with the program and we plan to enter the clinic in the first half of 2019. Learn about financial terms, types of investments, trading strategies and more. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. Tel: (+972) (3) 610-3100. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. Do Not Sell My Information. Wall Street analysts have given Mylan a "Buy" rating, but there may be better short-term opportunities in the market. PROXY STATEMENT FOR ANNUAL MEETING OF SHAREHOLDERS . Mylan has a P/B Ratio of 0.69. Controller, Sr. VP, Head of Strategic Global Quality & Regulatory Policy, Start Your Risk-Free Trial Subscription Here, Bloom Energy (NYSE: BE) is a Real Deal Fuel Cell EV Play, Here’s where the S&P 500 (NYSEARCA: SPY) Can Go From Here, Stephens Downgrades Teladoc Health (NYSE:TDOC) on Increasing Competition, Smith & Wesson Brands (NASDAQ:SWBI) Is Loaded For Double-Digit Gains, Buy Square (NYSE: SQ) For The 2021 Recovery Play, Take a Bite Out of Chewy (NYSE: CHWY) Ahead of Earnings, Betting On Tilly’s Inc (NYSE:TLYS) 12% Yield, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. PEG Ratios above 1 indicate that a company could be overvalued. According to analysts' consensus price target of $20.33, Mylan has a forecasted upside of 28.2% from its current price of $15.86. Intec Pharma Ltd. 2015 Equity Incentive Plan (Full title of the plan) Intec Pharma, Inc. 3 Columbus Circle - 15th Floor New York, NY 10019 (646) 374-8050 (Name, address, including zip code, and telephone number, including area code, of agent for service) With copies to: Shachar Hadar. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. "We are delighted to be continuing this collaboration with … Intec Pharma Ltd. was established and incorporated in Israel on October 23, 2000 as a private Israeli company under the name Orly Guy Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Mylan has a PEG Ratio of 2.01. View insider buying and selling activity for Mylan. In the past three months, Mylan insiders have not sold or bought any company stock. The company had revenue of $2.97 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan's stock is owned by a number of institutional and retail investors. Novartis and Intec are excited to conduct these studies to collect critical information to determine the program's clinical and commercial potential," stated Nadav Navon, Ph.D., chief operating officer of Intec Pharma. Intech Organics Ltd. 543 D, Pace City II, Sector 37 Gurugram – 122001, Haryana India High institutional ownership can be a signal of strong market trust in this company. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. MarketBeat just released five new trading ideas, but Mylan wasn't one of them. Intec pharma Ltd. 2015 equity incentive Plan . Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter. Mylan has received 753 “outperform” votes. Definitions . View which stocks have been most impacted by COVID-19. The purpose of this 2015 Equity Incentive Plan is to secure for Intec Pharma Ltd. and its shareholders the benefits arising from the provision of share based Awards to employees, officers, directors and Consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company’s future growth and success. JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase up to 16,250,000 ordinary shares, at a public offering price of … The Company's … There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Intec Pharma plans to move forward with a series of Phase 1 pharmacokinetic studies of each of these components alone and in combination, believing that exploring the individual components of cannabis provides the potential to pursue additional opportunities in target pain indications. The P/E ratio of Mylan is 29.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.58. Mylan is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021. The endocannabinoid system and mechanisms of pain reduction. Shares of MYL can be purchased through any online brokerage account. 16 Abba Hillel Silver Rd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering. To see all exchange delays and terms of use please see disclaimer. Get daily stock ideas top-performing Wall Street analysts. Please log in to your account or sign up in order to add this asset to your watchlist. 88.18% of the stock of Mylan is held by institutions. View insider buying and selling activity for Mylan. Mylan has received a consensus rating of Buy. Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. One Azrieli Center, … MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Ramat Gan 52506, Israel. Identify stocks that meet your criteria using seven unique stock screeners. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® (AP) platform technology. Mylan has only been the subject of 1 research reports in the past 90 days. © American Consumer News, LLC dba MarketBeat® 2010-2020. That closing price of NTEC’s stock is at a discount of -337.02% from its 52-week high price of $15.82 and is … The purpose of this Share Option Plan is to secure for Intec Pharma Ltd. and its shareholders the benefits arising from ownership of share capital by employees, officers, directors and consultants of the Company and its Affiliates (as defined below), who are expected to contribute to the Company’s future growth and success. Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. Learn more. Since then, MYL stock has increased by 9.6% and is now trading at $15.8550. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Mylan (NASDAQ:MYL) announced its earnings results on Friday, November, 6th. (Add your “underperform” vote.). All rights reserved. Mylan does not have a long track record of dividend growth. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. ), Mylan has received 632 “underperform” votes. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. MYL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Harel Insurance Investments & Financial Services Ltd., Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, JPMorgan Chase & Co., AXA S.A., and Cubist Systematic Strategies LLC. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Starbucks (SBUX) and General Electric (GE). Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. Export data to Excel for your own analysis. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Intec Pharma Ltd. 2015 Equity Incentive Plan (Full title of the plans) Vcorp Agent Services, Inc. 25 Robert Pitt Drive, Suite 204 Monsey, New York 10952 (888) 528-2677 (845) 818-3588 (facsimile) (Name, address, including zip code, and telephone number, including area code, of agent for service) With a copy to: Dr. Shachar Hadar, Adv. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Top institutional shareholders include BlackRock Inc. (8.36%), State Street Corp (4.65%), Pzena Investment Management LLC (3.32%), Camber Capital Management LP (2.22%), AQR Capital Management LLC (1.41%) and Samlyn Capital LLC (1.31%). Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit.

.

Long Lake Hunting Club, Clarissa Molina Height And Weight, Squad Mod Fifa 20, Spin Zone Bumper Cars For Sale, Michel Vorm Net Worth, Lesser Symbol Of Wrath, Is Sweetwater Legit Reddit, Where Was Rio Lobo Filmed, Cool Text Effects Copy And Paste, Grade Potential Tutoring Slo, Tropico 5 How To Open Trade Menu, Scientific Method Worksheet Pdf Answer Key, High Nuptial Mass, Nathan Sobey Salary, Highfields Toowoomba Things To Do,